Preterm Infant Inhaled Albuterol Dosing
Completed · Phase 4
Conditions studied: Bronchopulmonary Dysplasia, Very Low Birth Weight
In brief
The purpose of this study is to help determine the best dose of inhaled albuterol sulfate in premature babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic lung disease of prematurity and is associated with increased morbidity and mortality, longer hospital stays, and increased healthcare utilization. Albuterol is an inhaled medication frequently used in premature infants with chronic lung disease and in people with asthma. It is believed to be safe, but the optimal dose for infants is not clear. The investigators hypothesize that albuterol may help a subset of premature infants with lung disease, but they need to determine the best dose prior to doing research about how effective it is for chronic lung disease/BPD. Response to each of three doses of albuterol will be measure using pulmonary function tests.
Key facts
- Study ID
- NCT02447250
- Run by
- Oregon Health and Science University
- People needed
- 14
- Starts
- 2013-10-24
- Expected to finish
- 2014-12-30
- Last updated by the study team
- 2019-05-23
Who can join
Age: 0 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- very low birthweight infant (<1500g)
- gestational age at birth <32 weeks
- age 14 or more days and corrected to 28w0d to 33w6d gestational age
- continuing to require respiratory support and/or supplemental oxygen
You may not qualify if…
- chromosomal abnormalities
- major congenital anomalies
- congenital heart disease, except atrial septal defect and patent ductus arteriosus
- clinical providers determine subject too unstable to undergo pulmonary function testing
Where it is running
- Doernbecher Neonatal Care Center at Oregon Health & Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.